Peptide Antagonists
Peptide Antagonists - Related Videos
04:00
Immunoaffinity Based Extraction of Ubiquitinylated Peptides: A Technique to Selectively Extract Ubiquitin Tagged Peptides from Purified Peptide Fractions
0 Views •
2023
This video describes a method to extract and purify ubiquitinylated peptides containing remnant di-glycine peptides from a complex peptide mixture. The presented method may help in identifying original ubiquitination sites in the protein.
01:24
Cholinergic Antagonists: Pharmacokinetics
0 Views •
2023
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and the conjunctiva.
01:26
Cholinergic Antagonists: Therapeutic Uses
0 Views •
2023
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics: Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
01:28
Cholinergic Antagonists: Pharmacological Actions
0 Views •
2023
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics: Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
07:09
Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice
0 Views •
Cited by 7 •
2011
We describe procedures for repeated administration of inhibitors of muscarinic signaling to the levator auris longus (LAL) muscle of young adult mice and for subsequent immunostaining of its neuromuscular junctions (NMJs) in wholemounts. The LAL muscle has unique advantages for revealing in vivo pharmacological effects on NMJs.
FAQs
Their sequence occupies the receptor or protein-interaction site that a natural ligand would normally use. Because the target is engaged without the associated response, ligand-dependent activation is reduced or prevented. This competitive behavior makes binding-site occupancy the key mechanistic link between antagonist design and control of cellular signaling.
Altering the amino acid sequence can change how selectively and strongly a peptide recognizes its target. Structural constraints help preserve a binding shape, while chemical modifications can improve stability. Together, these design variables influence whether the antagonist remains intact, binds preferentially to the intended site, and blocks signaling effectively.
An agonist triggers the response associated with receptor engagement, whereas an antagonist is designed to retain target recognition without producing that response. This distinction allows the same general binding principle to be used for opposite experimental purposes: activating a pathway with an agonist or examining pathway dependence by blocking it with an antagonist.
Design focuses on the structural features that a natural ligand or protein-binding partner uses for recognition. Reproducing those key features can support competition at the relevant receptor or interaction site, while additional sequence changes or structural constraints can tune selectivity and binding strength. The intended target therefore guides both sequence choice and molecular refinement.
A conceptual workflow begins by identifying the receptor or protein-interaction site and the ligand features that should be mimicked. Candidate sequences can then be adjusted through sequence changes, chemical modifications, or structural constraints. Their value is assessed by whether they preserve target binding while avoiding the response normally produced by the natural ligand.
They are useful for probing receptor function and protein interactions because blocking a target can reveal how its signaling or binding contributes to a system. Beyond basic studies, the same design principles support targeted therapeutics, biosensors, and engineered biomaterials intended to modulate cellular behavior in a controlled way.